ω-Hydroxylation of farnesol by mammalian cytochromes P450

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1682, Issue 1-3, 2004, Pages 18-27

  DeBarber, Andrea E ^a   Bleyle, Lisa A ^a   Roullet, Jean Baptiste O ^b   Koop, Dennis R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

, prenyl dicarboxylic acids; (2E, 6E, 10E) 12 hydroxyfarnesol; CID; collision induced dissociation; CYP2C19; CYP2E1; Ethanol; farnesyl pyrophosphate; FPP; lipoprotein deficient serum; LPDS; thin layer chromatography; TLC; ZA; zaragozic acid

Indexed keywords

ACETONE; ALPHA,OMEGA PRENYL DICARBOXYLIC ACID; CARBON 14; CYTOCHROME P450 2C19; CYTOCHROME P450 2E1; DICARBOXYLIC ACID DERIVATIVE; FARNESOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; CATALYST; CONTROLLED STUDY; HOMEOSTASIS; HYDROXYLATION; ISOTOPE LABELING; MAMMAL; METABOLISM; METABOLITE; MICROSOME; NONHUMAN; PRIORITY JOURNAL; URINE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; CYTOCHROME P-450 CYP2E1; FARNESOL; HELA CELLS; HUMANS; HYDROXYLATION; MIXED FUNCTION OXYGENASES; RABBITS;

ANIMALIA; MAMMALIA;

EID: 2442688821     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2004.01.003     Document Type: Article

References (41)

1. Bergstrom J.D., Kurtz M.M., Rew D.J., Amend A.M., Karkas J.D., Bostedor R.G., Bansal V.S., Dufresne C., VanMiddlesworth F.L., Hensens O.D. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. U. S. A. 90:1993;80-84
2. Bansal V.S., Vaidya S. Characterization of two distinct allyl pyrophosphatase activities from rat liver microsomes. Arch. Biochem. Biophys. 315:1994;393-399
3. Meigs T.E., Simoni R.D. Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. Arch. Biochem. Biophys. 345:1997;1-9
4. Christophe J., Popjak G. Studies on the biosynthesis of cholesterol: XIV. the origin of prenoic acids from allyl pyrophosphates in liver enzyme systems. J. Lipid Res. 2:1961;244-257
5. Hampton R.Y., Bhakta H. Ubiquitin-mediated regulation of 3-hydroxy-3-methylglutaryl-CoA reductase. Proc. Natl. Acad. Sci. U. S. A. 94:1997;12944-12948
6. Keller R.K., Zhao Z., Chambers C., Ness G.C. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver. Arch. Biochem. Biophys. 328:1996;324-330
7. Correll C.C., Ng L., Edwards P.A. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 269:1994;17390-17393
8. Meigs T.E., Roseman D.S., Simoni R.D. Regulation of 3-hydroxy-3- methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J. Biol. Chem. 271:1996;7916-7922
9. Yazlovitskaya E.M., Melnykovych G. Selective farnesol toxicity and translocation of protein kinase C in neoplastic HeLa-S3K and non-neoplastic CF-3 cells. Cancer Lett. 88:1995;179-183
10. Haug J.S., Goldner C.M., Yazlovitskaya E.M., Voziyan P.A., Melnykovych G. Directed cell killing (apoptosis) in human lymphoblastoid cells incubated in the presence of farnesol: effect of phosphatidylcholine. Biochim. Biophys. Acta. 1223:1994;133-140
11. Miquel K.A., Pradines A., Terce F., Selmi S., Favre G. Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. J. Biol. Chem. 273:1998;26179-26186
12. 2+ channels in vascular smooth muscle cells. J. Biol. Chem. 19:1997;32240-32246
13. Roullet J.B., Xue H., Chapman J., McDougal P.C., Roullet C.M., McCarron D.A. Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J. Clin. Invest. 97:1996;2384-2390
14. Roullet J.B., Spaetgens R.L., Burlingame T., Feng Z.P., Zamponi G.W. Modulation of neuronal voltage-gated calcium channels by farnesol. J. Biol. Chem. 274:1999;25439-25446
15. Gonzalez-Pacanowska D.B., Arison B., Havel C.M., Watson J.A. Isopentenoid synthesis in isolated embryonic Drosophila cells. Farnesol catabolism and omega-oxidation. J. Biol. Chem. 263:1988;1301-1306
16. Vaidya S., Bostedor R., Kurtz M.M., Bergstrom J.D., Bansal V.S. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A. Arch. Biochem. Biophys. 355:1998;84-92
17. Bostedor R.G., Karkas J.D., Arison B.H., Bansal V.S., Vaidya S., Germershausen J.I., Kurtz M.M., Bergstrom J.D. Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. J. Biol. Chem. 272:1997;9197-9203
18. Westfall D.N., Aboushadi N., Shackelford J.E., Krisans S.K. Metabolism of farnesol: phosphorylation of farnesol by rat liver microsomal and peroxisomal fractions. Biochem. Biophys. Res. Commun. 230:1997;562-568
19. Bentinger M.J., Grunler J., Peterson E., Swiezewska E., Dallner G. Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase. Arch. Biochem. Biophys. 353:1998;191-198
20. Keung W.M. Human liver alcohol dehydrogenases catalyze the oxidation of the intermediary alcohols of the shunt pathway of mevalonate metabolism. Biochem. Biophys. Res. Commun. 174:1991;701-707
21. Asano M., Yamakawa T. The fate of branched chain fatty acids in the animal body I. A contribution to the problem of Hildebrandt acid. J. Biochem. 37:1950;321-327
22. Kuhn R., Kohler F., Kohler L. Uber methyl-oxydationen im tierkorper. Hoppe-Seyler Z. Physiol. Chem. 242:1936;171-197
23. Licht H.J., Coscia C.J. Cytochrome P-450LM2 mediated hydroxylation of monoterpene alcohols. Biochemistry. 17:1978;5638-5646
24. Raner G.M., Muir A.Q., Lowry C.W., Davis B.A. Farnesol as an inhibitor and substrate for rabbit liver microsomal P450 enzymes. Biochem. Biophys. Res. Commun. 293:2002;1-6
25. Bhalerao U.T., Plattner J.J., Rapoport H. Synthesis of dl-sirenin and dl-isosirenin. J. Am. Chem. Soc. 92:1970;3429-3434
26. Buchi G., Wuest H. Eine synthese des beta-sinensals. Helv. Chim. Acta. 50:1967;2440-2445
27. Koop D.R., Nordblom G.D., Coon M.J. Immunochemical evidence for a role of cytochrome P-450 in liver microsomal ethanol oxidation. Arch. Biochem. Biophys. 235:1984;228-238
28. Spatzenegger M., Liu H., Wang Q., Debarber A.E., Koop D.R., Halpert J.R. Analysis of differential substrate selectivities of CYP2B6 and CYP2E1 by site-directed mutagenesis and molecular modeling. J. Pharmacol. Exp. Ther. 304:2003;477-487
29. Barmada S., Kienle E., Koop D.R. Rabbit P450 2E1 expressed in CHO-K1 cells has a short half-life. Biochem. Biophys. Res. Commun. 206:1995;601-607
30. Huan J.Y., Koop D.R. Tightly regulated and inducible expression of rabbit CYP2E1 using a tetracycline-controlled expression system. Drug Metab. Dispos. 27:1999;549-554
31. Sutherland T.D., Unnithan G.C., Andersen J.F., Evans P.H., Murataliev M.B., Szabo L.Z., Mash E.A., Bowers W.S., Feyereisen R. A cytochrome P450 terpenoid hydroxylase linked to the suppression of insect juvenile hormone synthesis. Proc. Natl. Acad. Sci. U. S. A. 95:1998;12884-12889
32. Rettie A.E., Koop D.R., Haining R.L. CYP2C enzymes. Levy R.H., Thummel K.E., Trager W.F., Hansten P.D., Eichelbaum M. Metabolic Drug Interactions. 2000;75-86 Lippincot-Williams and Wilkins, Philadelphia, PA
33. Guan X.M., Fisher M.B., Lang D.H., Zheng Y.M., Koop D.R., Rettie A.E. Cytochrome P450-dependent desaturation of lauric acid: isoform selectivity and mechanism of formation of 11-dodecenoic acid. Chem. Biol. Interact. 110:1998;103-121
34. Laethem R.M., Balazy M., Falck J.R., Laethem C.L., Koop D.R. Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J. Biol. Chem. 268:1993;12912-12918
35. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U. S. A. 94:1997;4312-4317
36. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82:2002;131-185
37. O'Brien M.L., Rangwala S.M., Henry K.W., Weinberger C., Crick D.C., Waechter C.J., Feller D.R., Noonan D.J. Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis. Carcinogenesis. 17:1996;185-190
38. Hanley K., Komuves L.G., Ng D.C., Schoonjans K., He S.S., Lau P., Bikle D.D., Williams M.L., Elias P.M., Auwerx J., Feingold K.R. Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J. Biol. Chem. 275:2000;11484-11491
39. Kocarek T.A., Mercer-Haines N.A. Squalestatin 1-inducible expression of rat CYP2B: evidence that an endogenous isoprenoid is an activator of the constitutive androstane receptor. Mol. Pharmacol. 62:2002;1177-1186
40. Waller G.R. Dehydrogenation of trans-trans farnesol by horse liver alcohol dehydrogenase. Nature. 207:1965;1389-1390
41. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52:2001;349-355